Krystal Biotech Operating Expenses 2017-2024 | KRYS

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Krystal Biotech operating expenses from 2017 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Krystal Biotech operating expenses from 2017 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$146.3B
Gilead Sciences (GILD)	$114.5B
Bristol Myers Squibb (BMY)	$114.2B
Vertex Pharmaceuticals (VRTX)	$108.7B
CSL (CSLLY)	$83.4B
Regeneron Pharmaceuticals (REGN)	$74.9B
GSK (GSK)	$69.3B
Argenex SE (ARGX)	$38.7B
Alnylam Pharmaceuticals (ALNY)	$31.8B
BioNTech SE (BNTX)	$26.8B
Illumina (ILMN)	$21.7B
BeiGene (ONC)	$20.5B
Biogen (BIIB)	$20.5B
Incyte (INCY)	$13.9B
Genmab (GMAB)	$13.8B
Genmab (GNMSF)	$13.7B
Intra-Cellular Therapies (ITCI)	$13.4B
Moderna (MRNA)	$13.1B
Insmed (INSM)	$13B
Bio-Techne Corp (TECH)	$12B
BioMarin Pharmaceutical (BMRN)	$11.7B
Sarepta Therapeutics (SRPT)	$11.3B
Vaxcyte (PCVX)	$10.6B
QIAGEN (QGEN)	$10.5B
Exelixis (EXEL)	$10.3B
Swedish Orphan Biovitrum (BIOVF)	$10.1B
Exact Sciences (EXAS)	$9.6B
Bio-Rad Laboratories (BIO.B)	$9.5B
Repligen (RGEN)	$9B
Roivant Sciences (ROIV)	$8.1B